SpA | OA | |||||||
Cases (n=115) | Controls (n=455) | Crude OR | aOR* | Cases (n=6287) | Controls (n=25 164) | Crude OR | aOR* | |
Current† diclofenac | 25 | 62 | 2.23 (1.22 to 4.05) | 3.32 (1.57 to 7.03) | 843 | 2981 | 1.23 (1.12 to 1.34) | 1.26 (1.14 to 1.39) |
Current naproxen | 14 | 46 | 1.60 (0.81 to 3.18) | 1.19 (0.53 to 2.68) | 339 | 1365 | 1.06 (0.93 to 1.20) | 0.98 (0.85 to 1.13) |
Current other NSAID | 29 | 107 | 1.48 (0.84 to 2.61) | 1.23 (0.61 to 2.46) | 1224 | 4491 | 1.18 (1.09 to 1.28) | 1.17 (1.07 to 1.28) |
Recent† NSAID | 8 | 39 | 1.05 (0.45 to 2.44) | 1.03 (0.36 to 2.93) | 684 | 2805 | 1.05 (0.96 to 1.15) | 1.01 (0.91 to 1.12) |
Remote† NSAID | 39 | 201 | 1.0 (ref) | 1.0 (ref) | 3197 | 13 522 | 1.0 (ref) | 1.0 (ref) |
*Adjusted for potential confounders, using imputed BMI and smoking when missing.
†Current use: prescription date 0–180 days prior to index date; recent use: 180–365 days and remote use: >365 days.
aOR, adjusted OR; BMI, body mass index; NSAID, non-steroidal anti-inflammatory drug; OA, osteoarthritis; SpA, spondyloarthritis (includes ankylosing spondylitis and psoriatic arthritis).